3-methyl-1-phenylsulfonyl-2-butanone | 112683-61-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-1-phenylsulfonyl-2-butanone
• 英文别名: 3-methyl-1-(phenylsulfonyl)butan-2-one；1-(Benzenesulfonyl)-3-methylbutan-2-one
• CAS: 112683-61-1
• 化学式: C₁₁H₁₄O₃S
• 分子量: 226.296
• InChiKey: WRJYWIFGSQRUGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  63.5-64.5 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))
• 沸点：
  383.7±34.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methyl-1-phenylsulfonyl-2-butanone 在 phosphate buffer 、 葡萄糖 、 Pichia minuta IAM 12215 strain 作用下， 反应 27.5h， 以92%的产率得到(S)-(+)-3-methyl-1-phenylsulfonyl-2-butanol
  参考文献：
  名称：

  Screening, substrate specificity and stereoselectivity of yeast strains, which reduce sterically hindered isopropyl ketones

  摘要：

  Towards the synthesis of sterically hindered optically active secondary alcohol 2, yeast strains (Candida floricola IAM 13115 and Trichosporon cutaneum IAM 12206) with si-face hydride attack on isopropyl phenylsulfonylmethyl ketone I were developed by screening. Strains with complementary re-facial selectivity (Pichia angusta IAM 12895 and Pichia minuta IAM 12215) were also found. Based on the substrate specificity studies of these four strains, microbial reduction was applied to the synthesis of (3S, 5S)-2,6-dimethyl3, 5-heptanediol 12a. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.12.013
• 作为产物：
  描述：

  isobutyrylacetic acid 、 sodium benzenesulfonate 在 potassium phosphate 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以70%的产率得到3-methyl-1-phenylsulfonyl-2-butanone
  参考文献：
  名称：

  N-溴丁二酰亚胺介导的β-酮酸与亚磺酸钠对β-酮砜的脱羧磺酰化：评估人类羧酸酯酶1的活性

  摘要：

  开发了由N-溴琥珀酰亚胺（NBS）介导的β-酮酸与亚磺酸钠的脱羧磺酰化反应。该转化表现出广泛的底物范围和良好的官能团耐受性。初步的机理研究表明，该反应很可能通过磺酰溴途径对β-酮酸进行亲核取代而进行。评价所有合成的β-酮砜对人羧酸酯酶1（CES1）的抑制作用。这项研究为有效合成广泛存在于生物活性天然产物和药物制剂中的β-酮砜提供了一种简便的策略。

  DOI：

  10.1016/j.tet.2018.08.024

文献信息

• A mild and chemoselective CALB biocatalysed synthesis of sulfoxides exploiting the dual role of AcOEt as solvent and reagent
  作者：Silvia Anselmi、Siyu Liu、Seong-Heun Kim、Sarah M. Barry、Thomas S. Moody、Daniele Castagnolo

  DOI：10.1039/d0ob01966f

  日期：——

  Sulfoxides have been synthesised from various sulfide substrates under mild conditions exploiting CALB biocatalyst in the presence of urea hydrogen peroxide and AcOEt which acts with the dual role of solvent and reagent.

  砜氧化物已经在温和条件下利用CALB生物催化剂从各种硫醚底物合成，利用尿素过氧化氢和乙酸乙酯作为溶剂和试剂具有双重作用。
• Latrunculin-Based Macrolides and Their Uses
  申请人：El Sayed Khalid

  公开号：US20110136880A1

  公开（公告）日：2011-06-09

  Latrunculin derivatives are disclosed, as are anti-invasive and cytotoxic uses for latrunculins and latrunculin derivatives, and semisyntheses of latrunculin derivatives. The latrunculins and latrunculin derivatives are useful, for example, in treating cancers.

  本文披露了Latrunculin衍生物，以及Latrunculins和Latrunculin衍生物的抗侵袭和细胞毒性用途，以及Latrunculin衍生物的半合成方法。例如，Latrunculins和Latrunculin衍生物在治疗癌症方面是有用的。
• An Efficient Synthesis of Chiral β-Hydroxy Sulfones via Ru-Catalyzed Enantioselective Hydrogenation in the Presence of Iodine
  作者：Xiaobing Wan、Qinghua Meng、Hongwei Zhang、Yanhui Sun、Weizheng Fan、Zhaoguo Zhang

  DOI：10.1021/ol702565x

  日期：2007.12.1

  Ru-SUNPHOS catalyzed asymmetric hydrogenation of a variety of sulfonyl ketones (R = alkyl, aryl) in the presence of iodine gave enantioenriched hydroxyl sulfones with good catalytic efficiency. Further investigation revealed that the in situ generated anhydrous HI is the operating additive.

  Ru-SUNPHOS在碘的存在下催化多种磺酰基酮（R =烷基，芳基）的不对称氢化反应，得到了对映体富集的羟基砜，具有良好的催化效率。进一步的研究表明，原位生成的无水HI是工作添加剂。
• BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN
  申请人：Bradley Mark

  公开号：US20190106460A1

  公开（公告）日：2019-04-11

  The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (βTrCP), and modulate the activity of βTrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.

  本发明涉及与Beta Trans-ducin重复含蛋白（βTrCP）结合并调节βTrCP活性的化合物。特别是，本发明涉及表现出对PTrCP优化结合的化合物。本发明还涉及包含这种化合物的制药组合物以及将这种化合物用作药物的用途，特别是用于治疗与异常蛋白降解相关的疾病，如癌症。首选的结合抑制剂是从DSGXXS动机中派生的肽，例如DEGFWE，DDGFWD和Succinyl-EGFWE。
• VIRAL POLYMERASE INHIBITORS
  申请人：STAMMERS Timothy

  公开号：US20110230465A1

  公开（公告）日：2011-09-22

  Compounds of formula I: wherein X, R 2 , R 3 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

  式I的化合物：其中X、R2、R3、R5和R6的定义如本文所述，可用作丙型肝炎病毒NS5B聚合酶的抑制剂。